HC Wainwright & Co. Reiterates Buy on Legend Biotech, Maintains $65 Price Target
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Legend Biotech (NASDAQ:LEGN) with a Buy and maintains $65 price target.
Stocks · News reference
Legend Biotech Q2 Adj. EPS $0.16 Beats $0.07 Estimate, Sales $387.500M Beat $355.772M Estimate
Legend Biotech (NASDAQ:LEGN) reported quarterly earnings of $0.16 per share which beat the analyst consensus estimate of $0.07 by 100 percent. This is a 147.06 percent increase over losses of $(0.34) per share from the
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
This Apogee Therapeutics Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday
Analysts changed outlooks on top stocks. Raymond James downgraded ONON, Deutsche Bank downgraded ATAI, BTIG downgraded APGE.
Morgan Stanley Maintains Overweight on Legend Biotech, Raises Price Target to $49
Morgan Stanley analyst Matthew Harrison maintains Legend Biotech (NASDAQ:LEGN) with a Overweight and raises the price target from $48 to $49.
TD Cowen Maintains Hold on Legend Biotech, Lowers Price Target to $24
TD Cowen analyst Yaron Werber maintains Legend Biotech (NASDAQ:LEGN) with a Hold and lowers the price target from $29 to $24.